Dermira Inc. plans to sell $110 million of its common shares in an underwritten public offering.
The biopharmaceutical company plans to grant the underwriters an option to buy up to an additional $16.5 million of its common stock in the offering.
Citigroup, Cowen, Cantor Fitzgerald & Co. and Guggenheim Securities are acting as book-runners, with Needham & Co. and H.C. Wainwright & Co. as co-managers.
Menlo Park, Calif.-based Dermira develops and commercializes therapies for patients with skin conditions. The company offers Qbrexza for the treatment of primary axillary hyperhidrosis — a certain condition in which excessive sweating occurs — in adults and pediatric patients nine years and older.